[Treatment of obstructive aortic atheroma in homozygotic familial hypercholesterolemia]

M Laali1, D Thomas, R Isnard

  • 1Service de Chirurgie Thoracique et Cardiovasculaire, Hôpital La Pitié-Salpêtrière, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|August 2, 2006
PubMed

Insights

This report details a surgical approach for homozygotic familial hypercholesterolaemia (HFH) involving aortic valve, ascending aorta, and coronary ostia. The single-procedure surgery successfully corrected all abnormalities in three patients, showing favorable outcomes.

Area of Science:

  • Cardiovascular Surgery
  • Genetics
  • Metabolic Disorders

Context:

  • Homozygotic familial hypercholesterolaemia (HFH) is a rare genetic disorder.
  • HFH can manifest with severe cardiovascular complications, including valvular and coronary artery stenosis.
  • This specific HFH phenotype involves aortic valve, ascending aorta, and coronary ostia.

Purpose:

  • To describe a surgical technique for treating a rare form of HFH.
  • To detail the correction of combined valvular, supravalvular, and coronary ostial stenosis in HFH patients.
  • To report the outcomes of a multi-component surgical intervention for complex HFH.

Summary:

  • Three HFH patients with left ventricular ejection obstruction and myocardial ischemia underwent a single-procedure surgery.
  • The surgery included aortic valve replacement, ascending aortic replacement, and coronary ostia widening with reimplantation.
  • Postoperative results were favorable, with normalized cardiac function and unobstructed coronary arteries.

Impact:

  • The described surgical strategy offers a comprehensive solution for complex HFH cardiovascular manifestations.
  • This approach aims for good long-term results in patients with severe, multi-site aortic and coronary disease.
  • Highlights the importance of addressing all affected cardiovascular structures in this rare HFH variant.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...